Barclays analyst Emily Field raised the firm’s price target on Novartis (NVS) to CHF 90 from CHF 85 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis AG Earnings Call Highlights Strong Growth and Strategic Challenges
- Navigating Risks: Novartis’s Strategic Challenges in Expanding Innovative Medicines Portfolio
- Novartis AG Reports Strong Sales Growth and Innovation
- Ionis ‘remains confident in pelacarsen’ after Novartis update on Phase 3 timing
- Morning Movers: Apple and Exxon higher following quarterly earnings